Vamil Divan
Stock Analyst at Guggenheim
(4.82)
# 65
Out of 5,180 analysts
250
Total ratings
69.06%
Success rate
19.89%
Average return
Main Sectors:
Stocks Rated by Vamil Divan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Buy | $35 → $36 | $27.77 | +29.64% | 24 | Mar 24, 2026 | |
| JBIO Jade Biosciences | Maintains: Buy | $17 → $23 | $13.26 | +73.45% | 3 | Mar 11, 2026 | |
| MRK Merck & Co. | Maintains: Buy | $122 → $140 | $118.10 | +18.54% | 15 | Feb 6, 2026 | |
| AMGN Amgen | Maintains: Neutral | $305 → $347 | $349.00 | -0.57% | 2 | Feb 6, 2026 | |
| JNJ Johnson & Johnson | Maintains: Buy | $227 → $240 | $242.49 | -1.03% | 19 | Jan 23, 2026 | |
| ANIP ANI Pharmaceuticals | Maintains: Buy | $115 → $124 | $73.71 | +68.23% | 14 | Jan 16, 2026 | |
| INSM Insmed | Maintains: Buy | $230 → $221 | $153.32 | +44.14% | 8 | Dec 18, 2025 | |
| ELDN Eledon Pharmaceuticals | Maintains: Buy | $9 → $8 | $2.71 | +195.20% | 1 | Nov 18, 2025 | |
| SCYX SCYNEXIS | Maintains: Buy | $4 → $3 | $0.79 | +279.89% | 3 | Oct 28, 2025 | |
| ABBV AbbVie | Maintains: Buy | $227 → $242 | $213.12 | +13.55% | 28 | Oct 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $11 | $5.05 | +117.82% | 2 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $13 | $6.24 | +108.50% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $39 | $26.64 | +46.40% | 2 | Sep 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $7 | $1.62 | +332.10% | 2 | Jul 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $6.11 | +882.00% | 1 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $47 | $27.66 | +69.92% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.76 | +262.32% | 3 | Mar 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $59 → $61 | $38.10 | +60.10% | 5 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $10.68 | - | 5 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $26 | $6.38 | +307.52% | 2 | Jun 15, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $0.32 | - | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $27 → $19 | $21.07 | -9.82% | 7 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $95 → $98 | $128.72 | -23.87% | 8 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $34 | $30.15 | +12.77% | 13 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $2.47 | +304.86% | 3 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 → $49 | $160.50 | -69.47% | 3 | May 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $356 | $886.63 | -59.85% | 17 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $6 | $5.60 | +7.14% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $144 → $154 | $8.09 | +1,803.58% | 9 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $15 | $3.94 | +280.71% | 5 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $28.84 | - | 6 | Dec 13, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | n/a | $28.35 | - | 13 | Jul 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $15 | $13.40 | +11.94% | 4 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $58 → $61 | $59.73 | +2.13% | 8 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $103 | $2.63 | +3,816.35% | 3 | Jan 17, 2018 |
Pfizer
Mar 24, 2026
Maintains: Buy
Price Target: $35 → $36
Current: $27.77
Upside: +29.64%
Jade Biosciences
Mar 11, 2026
Maintains: Buy
Price Target: $17 → $23
Current: $13.26
Upside: +73.45%
Merck & Co.
Feb 6, 2026
Maintains: Buy
Price Target: $122 → $140
Current: $118.10
Upside: +18.54%
Amgen
Feb 6, 2026
Maintains: Neutral
Price Target: $305 → $347
Current: $349.00
Upside: -0.57%
Johnson & Johnson
Jan 23, 2026
Maintains: Buy
Price Target: $227 → $240
Current: $242.49
Upside: -1.03%
ANI Pharmaceuticals
Jan 16, 2026
Maintains: Buy
Price Target: $115 → $124
Current: $73.71
Upside: +68.23%
Insmed
Dec 18, 2025
Maintains: Buy
Price Target: $230 → $221
Current: $153.32
Upside: +44.14%
Eledon Pharmaceuticals
Nov 18, 2025
Maintains: Buy
Price Target: $9 → $8
Current: $2.71
Upside: +195.20%
SCYNEXIS
Oct 28, 2025
Maintains: Buy
Price Target: $4 → $3
Current: $0.79
Upside: +279.89%
AbbVie
Oct 20, 2025
Maintains: Buy
Price Target: $227 → $242
Current: $213.12
Upside: +13.55%
Sep 9, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $5.05
Upside: +117.82%
Sep 8, 2025
Maintains: Buy
Price Target: $14 → $13
Current: $6.24
Upside: +108.50%
Sep 8, 2025
Maintains: Buy
Price Target: $31 → $39
Current: $26.64
Upside: +46.40%
Jul 14, 2025
Maintains: Buy
Price Target: $6 → $7
Current: $1.62
Upside: +332.10%
Apr 21, 2025
Initiates: Buy
Price Target: $60
Current: $6.11
Upside: +882.00%
Apr 14, 2025
Reiterates: Buy
Price Target: $47
Current: $27.66
Upside: +69.92%
Mar 20, 2025
Reiterates: Buy
Price Target: $10
Current: $2.76
Upside: +262.32%
Feb 27, 2025
Maintains: Buy
Price Target: $59 → $61
Current: $38.10
Upside: +60.10%
Jan 17, 2025
Reiterates: Neutral
Price Target: n/a
Current: $10.68
Upside: -
Jun 15, 2023
Reiterates: Buy
Price Target: $26
Current: $6.38
Upside: +307.52%
Mar 1, 2023
Initiates: Neutral
Price Target: n/a
Current: $0.32
Upside: -
Aug 10, 2022
Maintains: Neutral
Price Target: $27 → $19
Current: $21.07
Upside: -9.82%
Aug 8, 2022
Maintains: Neutral
Price Target: $95 → $98
Current: $128.72
Upside: -23.87%
Jul 28, 2022
Maintains: Buy
Price Target: $36 → $34
Current: $30.15
Upside: +12.77%
May 25, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $2.47
Upside: +304.86%
May 3, 2022
Maintains: Buy
Price Target: $51 → $49
Current: $160.50
Upside: -69.47%
May 2, 2022
Maintains: Buy
Price Target: $315 → $356
Current: $886.63
Upside: -59.85%
Mar 16, 2022
Maintains: Buy
Price Target: $8 → $6
Current: $5.60
Upside: +7.14%
Mar 3, 2022
Maintains: Buy
Price Target: $144 → $154
Current: $8.09
Upside: +1,803.58%
May 6, 2021
Upgrades: Buy
Price Target: $15
Current: $3.94
Upside: +280.71%
Dec 13, 2019
Downgrades: Neutral
Price Target: n/a
Current: $28.84
Upside: -
Jul 10, 2019
Assumes: Neutral
Price Target: n/a
Current: $28.35
Upside: -
Aug 15, 2018
Assumes: Outperform
Price Target: $15
Current: $13.40
Upside: +11.94%
Jul 27, 2018
Maintains: Neutral
Price Target: $58 → $61
Current: $59.73
Upside: +2.13%
Jan 17, 2018
Initiates: Outperform
Price Target: $103
Current: $2.63
Upside: +3,816.35%